Research Interests
Experimental Therapeutics:
Studying pharmacokinetics and biopharmaceutics of potential candidate molecules (synthetic as well as of natural origin) of CSIR-CDRI drug
R&D pipeline (in addition to marketed drugs/metabolites/natural products) and deciphering the molecular mechanism(s) of ADME/disposition thereof.
Research Area
Bio-analysis
Bio-analytical method development and validation, as per the regulatory (US-FDA, ICH etc.) guidelines, on HPLC and LC-MS/MS platform for quantitative determination of small molecules (NCEs/Drugs and/or metabolites) in different biological matrices
Pharmacokinetic
Characterization of the in vivo pharmacokinetics (bio-availability, dose-proportionality, gender variation, inter-species comparison) following oral and
parenteral routes of administration in animal models. Toxicokinetic and tissue distribution studies to support regulatory toxicology
Metabolism, Metabolite Identification and CYP Phenotyping
In vitro/in vivo Metabolism of new chemical entities and/or drugs using animal models, scaling preclinical and in-vitro data to predict events in humans for
preliminary assessment of safe exposure levels, determination of the metabolite profiles of drug candidates using liver microsomes/human recombinant CYP450
isozymes, Identify Phase I or Phase II enzymes responsible for metabolite formation, predict drug interactions due to inhibition or induction of drug
metabolizing enzymes.
Interaction
Drug-drug, herb-drug and food-drug interaction studies for suggesting benefits (as potential combination)/risks of the same in therapies.
Biopharmaceutics
Permeability/Absorption Characterization Studies across Parallel Artificial Membrane Permeability Assay (PAMPA) and in situ rat model, Protein Binding and Simulated Gastro-intestinal Stability for new chemical entities/drugs.